193 related articles for article (PubMed ID: 12199719)
1. Postmarketing surveillance of new antiepileptic drugs: the tribulations of trials.
French JA
Epilepsia; 2002 Sep; 43(9):951-5. PubMed ID: 12199719
[No Abstract] [Full Text] [Related]
2. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy.
Epilepsia; 1998 Jul; 39(7):799-803. PubMed ID: 9670910
[No Abstract] [Full Text] [Related]
3. Postmarketing modifications in the safety labeling of the new antiepileptics.
Buck ML; Gurka MJ; Goodkin HP
Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
[No Abstract] [Full Text] [Related]
4. Obstacles encountered in designing antiepileptic drug trials.
French JA
Epilepsy Res Suppl; 1993; 10():81-9. PubMed ID: 8251107
[No Abstract] [Full Text] [Related]
5. What's the problem with generic antiepileptic drugs?: a call to action.
Berg MJ
Neurology; 2007 Apr; 68(16):1245-6. PubMed ID: 17438211
[No Abstract] [Full Text] [Related]
6. The role of the pharmacist in investigational AED trials.
Graves NM
Epilepsy Res Suppl; 1993; 10():201-9. PubMed ID: 8251098
[No Abstract] [Full Text] [Related]
7. Postmarketing surveillance for drug abuse.
Arfken CL; Cicero TJ
Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S97-105. PubMed ID: 12759200
[TBL] [Abstract][Full Text] [Related]
8. A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England.
Wilton LV; Shakir S
Epilepsia; 2002 Sep; 43(9):983-92. PubMed ID: 12199723
[TBL] [Abstract][Full Text] [Related]
9. [The stakes of pre- and post-market authorization development and clinical assessment].
Schwebig A
Presse Med; 2012 May; 41 Suppl 1():S6-8. PubMed ID: 22483770
[No Abstract] [Full Text] [Related]
10. Safety in numbers--monitoring risk in approved drugs.
Okie S
N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
[No Abstract] [Full Text] [Related]
11. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
12. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
13. Medical devices on trial, Part I.
Wright D
Med Device Technol; 2002 Dec; 13(10):35-8. PubMed ID: 12575529
[TBL] [Abstract][Full Text] [Related]
14. [Experiences and reflections in the paediatric context - From label to delivery of an innovative treatment: what a journey! (1)].
Cancès C
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():32-34. PubMed ID: 30943159
[No Abstract] [Full Text] [Related]
15. Prototype antiepileptic drug clinical development plan.
Kramer LD; Pledger GW; Kamin M
Epilepsia; 1993; 34(6):1075-84. PubMed ID: 8243359
[TBL] [Abstract][Full Text] [Related]
16. Prescriber profile and post-marketing surveillance.
Inman W; Pearce G
Lancet; 1993 Sep; 342(8872):658-61. PubMed ID: 8103150
[TBL] [Abstract][Full Text] [Related]
17. Data from regulatory studies: What do they tell? What don't they tell?
Ben-Menachem E
Acta Neurol Scand Suppl; 2005; 181():21-5. PubMed ID: 16238704
[TBL] [Abstract][Full Text] [Related]
18. Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom.
Wong IC; Mawer GE; Sander JW
Epilepsia; 2001 Feb; 42(2):237-44. PubMed ID: 11240596
[TBL] [Abstract][Full Text] [Related]
19. [The need for 'postmarketing surveillance'].
Stricker BH; in 't Veld BA; Feenstra J
Ned Tijdschr Geneeskd; 1999 Apr; 143(14):711-3. PubMed ID: 10347624
[TBL] [Abstract][Full Text] [Related]
20. A survey of antiepileptic prescribing to women of childbearing potential in psychiatry.
Wieck A; Rao S; Sein K; Haddad PM
Arch Womens Ment Health; 2007; 10(2):83-5. PubMed ID: 17380253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
